Big milestone for #stroke care: #FDA formally approves Roche's TNKase for acute ischemic stroke after years of off-label use. Great to see regulatory alignment with clinical practice! More importantly, it's a sign of momentum in stroke drug development - expect more progress from companies like Astrocyte Pharmaceuticals in the near future! https://lnkd.in/etCNhAms
Astrocyte Pharmaceuticals
ç”Ÿç‰©æŠ€æœ¯ç ”ç©¶
Groton，Connecticut 565 ä½å…³æ³¨è€…
A Novel Approach to Neuroprotection
关于我们
Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
- 网站
-
https://www.astrocytepharma.com
Astrocyte Pharmaceuticals的外部链接
- 所属行业
- ç”Ÿç‰©æŠ€æœ¯ç ”ç©¶
- 规模
- 2-10 人
- 总部
- Groton，Connecticut
- 类型
- ç§äººæŒè‚¡
地点
-
主è¦
获å–路线
93 Shennecossett Rd
US，Connecticut，Groton，06340
-
获å–路线
245 First Street, STE 1800
US，MA，Cambridge，02142
Astrocyte Pharmaceuticals员工
-
Jeffrey Arnold
Angel Investor, Strategic Advisor, Director and Chairman
-
William Korinek
CEO and Co-Founder at Astrocyte Pharmaceuticals
-
Kevin Sheth
Director, Center for Brain & Mind Health at Yale University School of Medicine
-
Jim Lechleiter , Ph D.
Professor of Cell Systems & Anatomy at UT Health San Antonio
动æ€
-
Astrocyte Pharmaceuticals转å‘了
Tune in to the latest podcast with Timothy Dougherty and BiotechInsights to hear the story behind the founding of Astrocyte Pharmaceuticals, the promising potential of the AST-004 therapeutic for treating #stroke and #TBI, insights into the evolving world of #neuroprotection R&D, and valuable advice for aspiring scientific founders!
With over 1.5 million people suffering traumatic #brain injuries a year, 800,000 #stroke victims, and millions of concussions, the impact that brain impairment has on society is not to be ignored. We spoke with William Korinek of Astrocyte Pharmaceuticals, who is developing neuroprotective therapies for these conditions. Show link in comments.
-
Astrocyte Pharmaceuticals转å‘了
Astrocyte's successful Phase 1 First-in-Human Trial of AST-004 now published in the journal Stroke by Lisa Manna, MBA RN, Juan Hernandez, Dawn Hunt, Dr. Géza Lakner, Mark Matson, Rusty Poe, Ph.D., PMP, Robert Lancey, and Ted Liston! https://lnkd.in/ekdZa6SU #stroke #TBI
-
-
We’re excited to share our latest advances in brain injury treatment! Learn how we’re advancing neuroprotection for #stroke and #TBI #concussion .
Astrocyte Pharmaceuticals is proud to be leading the way in neuroprotection! Discover how our novel approach could change the future of brain injury care at https://lnkd.in/erugYzyE Jim Lechleiter , Ph D. & Ted Liston
-
-
Innovator of the Month!
It's an honor to have Astrocyte Pharmaceuticals and our innovative Connecticut research recognized by Senator Chris Murphy! https://lnkd.in/ewwPSSD7 Ted Liston, Rusty Poe, Ph.D., PMP
-
-
New broad-ranging podcast conversation between Astrocyte Pharmaceuticals' CEO William Korinek and Vial's Amy Del Medico - click to learn more about #astrocytes, #neuroprotection and the advancement of new potential treatments!
Explore the fascinating world of neuroprotection and astrocyte science with William Korinek of Astrocyte Pharmaceuticals. Gain insights into the promising future of therapies aiming to safeguard brain function and well-being. Check out the full episode of First in Human wherever you get your podcasts: ??Spotify: https://lnkd.in/gMcFJce4 ??Apple: https://lnkd.in/dxWnKiDa ??YouTube: https://lnkd.in/gF9erExX ??Transcript: https://lnkd.in/gzqybTcZ